Our Story
Spectral AI is an artificial intelligence company focusing on medical diagnostics, predictive analytics, and ‘Day One’ healing predictions.
-
2013
Spectral AI Incorporated
-
2014
DeepView Generation 1 510(k) clearance
-
2015
First BARDA Contract
-
2016
DeepView Generation 2 (510k) clearance
-
2017
First Defense Health Agency Contract
-
2018
FDA Breakthrough Designation – Burn
-
2019
Burn Proof Concept Clinical Study Initiated
-
2020
DFU Proof of Concept Clinical Study Initiated
-
2021
Secondary BARDA Burn Contract
-
2021
Burn AI Training Study Initiated
-
2021
Admission to Trading on AIM London Exchange
-
2021
First Department of Defense Contract
-
2022
DFU Validation Study Initiated
-
2023
EU DFU Clinical Study Initiation
-
2023
Business Combination Agreement
-
2024
Spectral AI Completes Truthing of Burn Center Images, Initiates Emergency Department Image Review
-
2024
Spectral AI Raises Up to $5 Million Financing Strengthening Financial Position for FDA Pathway
-
2025
Spectral AI Completes Data Analysis for U.S. Burn Pivotal Study
-
2025
FDA Submission of DeepView AI® System
-
2025
Spectral AI Named to TIME’s List of World’s Top HealthTech Companies 2025
At The Forefront
of Innovation
Provides faster and more accurate treatment insight, significantly improving patient care and clinical outcomes.
Let’s Talk
Want to Learn More About Spectral AI, DeepView®, and our Team?